A new market research report projects growth for the global asthma and chronic obstructive pulmonary disease prescription drug market. The report, published by RnRMarketResearch.com, valued the market at $34.9 billion in 2011 and projects it will reach $38 billion in 2012 and $47.1 billion in 2017, increasing at a 5-year compound annual growth rate (CAGR) of 4.4%.
The report, titled “Global Markets for Asthma & COPD Drugs,” further states that combination asthma/COPD drugs are expected to be worth $17.4 billion in 2012 and should reach $21.3 billion in 2017, a CAGR of 4.1%. The asthma drug market segment is projected to increase from $15.3 billion in 2012 to $20.2 billion in 2017, a CAGR or 5.7%. Meanwhile, the COPD drug segment is expected to increase from $5.3 billion in 2012 to $5.6 billion in 2017, a CAGR of 1.2%.
According to the report, while the loss of patent protection on several major COPD and asthma drugs between 2010 and 2017 will result in the cost for some treatments decreasing as generic versions gain market share, several new drugs are projected to enter the market through 2017, and they will continue to drive growth of revenues for asthma and COPD drugs.